Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Cognate BioServices and Nucleus Biologics Partnership n Cell and Gene Therapies

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

January 27, 2021

Cognate BioServices and Nucleus Biologics partnership will allow for custom and commercial medias and delivery systems for Cell and Gene Therapy clients.

“We’re quite excited to be moving forward with Nucleus,” said J. Kelly Ganjei, Cognate’s Chief Executive Officer. “I am particularly pleased with this collaboration that has come to us from the front lines of product development. Seeing an opportunity to simplify the supply chain, our sales and business development team seized this opportunity. I applaud my team and Nucleus for their creativity and vision in getting this partnership off the ground.”

Nucleus‘ AI formulation platform creates an optimized media offering that will allow Cognate’s clients to reduce time in development and towards large scale production. The partnership between Cognate and Nucleus will improve stability, reproducibility and supply-chain integrity for clients by enabling an on-demand supply of proprietary media from clinical to commercial scale. “Nucleus’ approach is a game changer in Cell and Gene Therapy manufacturing,” added Mr. Ganjei.

This partnership will focus on both clinical and commercial clients, especially as Cognate expands its business with both allogeneic and autologous on-demand cell and gene therapies. The Nucleus platform is unique within the cell and gene therapy supply chain and provides a scalable solution to rapidly formulate optimized media and receive custom media lots. This remarkably robust platform will enable Cognate to rapidly implement this technology across its global capacity network.

“We’re eager to get our partnership with Nucleus out to the market,” said Mike Stella, Cognate’s Chief Business Officer. “Nucleus’ product pipeline will improve stability, reproducibility, and reduce time to large-scale production. Critical components like media have been front and center for a while in our industry, but the constraints have been further amplified with COVID. We believe this will become another key differentiator for our business.”

“We are grateful for the opportunity to work with Kelly and his team at Cognate,” said David Sheehan, Founder, President and CEO of Nucleus Biologics.  “Cognate understands the industry, the clients’ needs, as well as the urgency with which the industry must create a new paradigm for media. Our approach promotes therapies getting into the clinic quicker, safer and more reliably, with less supply chain risk, and ultimately results in patients getting product more timely.  We are laser focused on building disruptive products, especially as it pertains to the supply chain of advanced therapy developers, and we are excited to have Cognate as a partner.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine